135 related articles for article (PubMed ID: 26479144)
1. Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy.
Greene SJ; Epstein SE; Kim RJ; Quyyumi AA; Cole RT; Anderson AS; Wilcox JE; Skopicki HA; Sikora S; Verkh L; Tankovich NI; Gheorghiade M; Butler J
J Cardiovasc Med (Hagerstown); 2017 Apr; 18(4):283-290. PubMed ID: 26479144
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial.
Butler J; Epstein SE; Greene SJ; Quyyumi AA; Sikora S; Kim RJ; Anderson AS; Wilcox JE; Tankovich NI; Lipinski MJ; Ko YA; Margulies KB; Cole RT; Skopicki HA; Gheorghiade M
Circ Res; 2017 Jan; 120(2):332-340. PubMed ID: 27856497
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial).
Mathiasen AB; Jørgensen E; Qayyum AA; Haack-Sørensen M; Ekblond A; Kastrup J
Am Heart J; 2012 Sep; 164(3):285-91. PubMed ID: 22980293
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Effects of Combined Cell Therapy for Chronic Ischemic Cardiomyopathy.
Karantalis V; Suncion-Loescher VY; Bagno L; Golpanian S; Wolf A; Sanina C; Premer C; Kanelidis AJ; McCall F; Wang B; Balkan W; Rodriguez J; Rosado M; Morales A; Hatzistergos K; Natsumeda M; Margitich I; Schulman IH; Gomes SA; Mushtaq M; DiFede DL; Fishman JE; Pattany P; Zambrano JP; Heldman AW; Hare JM
J Am Coll Cardiol; 2015 Nov; 66(18):1990-1999. PubMed ID: 26516002
[TBL] [Abstract][Full Text] [Related]
6. Why do patients with ischemic cardiomyopathy and a substantial amount of viable myocardium not always recover in function after revascularization?
Schinkel AF; Poldermans D; Rizzello V; Vanoverschelde JL; Elhendy A; Boersma E; Roelandt JR; Bax JJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):385-90. PubMed ID: 14762345
[TBL] [Abstract][Full Text] [Related]
7. Study design and rationale for ELPIS: A phase I/IIb randomized pilot study of allogeneic human mesenchymal stem cell injection in patients with hypoplastic left heart syndrome.
Kaushal S; Wehman B; Pietris N; Naughton C; Bentzen SM; Bigham G; Mishra R; Sharma S; Vricella L; Everett AD; Deatrick KB; Huang S; Mehta H; Ravekes WA; Hibino N; Difede DL; Khan A; Hare JM
Am Heart J; 2017 Oct; 192():48-56. PubMed ID: 28938963
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure.
Borow KM; Yaroshinsky A; Greenberg B; Perin EC
Circ Res; 2019 Jul; 125(3):265-281. PubMed ID: 31318648
[TBL] [Abstract][Full Text] [Related]
10. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study).
Florea V; Rieger AC; DiFede DL; El-Khorazaty J; Natsumeda M; Banerjee MN; Tompkins BA; Khan A; Schulman IH; Landin AM; Mushtaq M; Golpanian S; Lowery MH; Byrnes JJ; Hendel RC; Cohen MG; Valasaki K; Pujol MV; Ghersin E; Miki R; Delgado C; Abuzeid F; Vidro-Casiano M; Saltzman RG; DaFonseca D; Caceres LV; Ramdas KN; Mendizabal A; Heldman AW; Mitrani RD; Hare JM
Circ Res; 2017 Nov; 121(11):1279-1290. PubMed ID: 28923793
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy.
Bello D; Shah DJ; Farah GM; Di Luzio S; Parker M; Johnson MR; Cotts WG; Klocke FJ; Bonow RO; Judd RM; Gheorghiade M; Kim RJ
Circulation; 2003 Oct; 108(16):1945-53. PubMed ID: 14557364
[TBL] [Abstract][Full Text] [Related]
12. Reparative effects of allogeneic mesenchymal precursor cells delivered transendocardially in experimental nonischemic cardiomyopathy.
Psaltis PJ; Carbone A; Nelson AJ; Lau DH; Jantzen T; Manavis J; Williams K; Itescu S; Sanders P; Gronthos S; Zannettino AC; Worthley SG
JACC Cardiovasc Interv; 2010 Sep; 3(9):974-83. PubMed ID: 20850099
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).
Paitazoglou C; Bergmann MW; Vrtovec B; Chamuleau SAJ; van Klarenbosch B; Wojakowski W; Michalewska-Włudarczyk A; Gyöngyösi M; Ekblond A; Haack-Sørensen M; Jaquet K; Vrangbaek K; Kastrup J;
Eur J Heart Fail; 2019 Aug; 21(8):1032-1041. PubMed ID: 30790396
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional regeneration enhancement pilot trial in patients with nonischemic dilated cardiomyopathy.
Fischer-Rasokat U; Assmus B; Seeger FH; Honold J; Leistner D; Fichtlscherer S; Schächinger V; Tonn T; Martin H; Dimmeler S; Zeiher AM
Circ Heart Fail; 2009 Sep; 2(5):417-23. PubMed ID: 19808371
[TBL] [Abstract][Full Text] [Related]
15. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy.
Trachtenberg B; Velazquez DL; Williams AR; McNiece I; Fishman J; Nguyen K; Rouy D; Altman P; Schwarz R; Mendizabal A; Oskouei B; Byrnes J; Soto V; Tracy M; Zambrano JP; Heldman AW; Hare JM
Am Heart J; 2011 Mar; 161(3):487-93. PubMed ID: 21392602
[TBL] [Abstract][Full Text] [Related]
17. Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial.
Bolli R; Hare JM; Henry TD; Lenneman CG; March KL; Miller K; Pepine CJ; Perin EC; Traverse JH; Willerson JT; Yang PC; Gee AP; Lima JA; Moyé L; Vojvodic RW; Sayre SL; Bettencourt J; Cohen M; Ebert RF; Simari RD;
Am Heart J; 2018 Jul; 201():54-62. PubMed ID: 29910056
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy.
Haghikia A; Podewski E; Berliner D; Sonnenschein K; Fischer D; Angermann CE; Böhm M; Röntgen P; Bauersachs J; Hilfiker-Kleiner D
Clin Res Cardiol; 2015 Nov; 104(11):911-7. PubMed ID: 26026286
[TBL] [Abstract][Full Text] [Related]
19. Human Umbilical Cord-Derived Mesenchymal Stromal Cells Improve Left Ventricular Function, Perfusion, and Remodeling in a Porcine Model of Chronic Myocardial Ischemia.
Liu CB; Huang H; Sun P; Ma SZ; Liu AH; Xue J; Fu JH; Liang YQ; Liu B; Wu DY; Lü SH; Zhang XZ
Stem Cells Transl Med; 2016 Aug; 5(8):1004-13. PubMed ID: 27334487
[TBL] [Abstract][Full Text] [Related]
20. Hybrid transcatheter left ventricular reconstruction for the treatment of ischaemic cardiomyopathy.
Zivelonghi C; Klein P; Swaans MJ; Agostoni P
EuroIntervention; 2018 Mar; 13(16):1899-1901. PubMed ID: 28966158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
